检索结果 - Anthony W. Tolcher

Refine Results
  1. 1
    Antibody drug conjugates: lessons from 20 years of clinical experience

    Antibody drug conjugates: lessons from 20 years of clinical experience 由 Anthony W. Tolcher

    出版 2016
    获取全文
    Revisão
    加到收藏夹
    Saved in:
  2. 2
    The Evolution of Antibody-Drug Conjugates: A Positive Inflexion Point

    The Evolution of Antibody-Drug Conjugates: A Positive Inflexion Point 由 Anthony W. Tolcher

    出版 2020
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  3. 3
    Chemosensitization and Delayed Androgen-Independent Recurrence of Prostate Cancer With the Use of Antisense Bcl-2 Oligodeoxynucleotides

    Chemosensitization and Delayed Androgen-Independent Recurrence of Prostate Cancer With the Use of Antisense Bcl-2 Oligodeoxynucleotides 由 Hideaki Miayake, Anthony W. Tolcher, Martin Gleave

    出版 2000
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  4. 4
    Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors

    Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors 由 Anthony W. Tolcher, Wei Peng, Emiliano Calvo

    出版 2018
    获取全文
    Revisão
    加到收藏夹
    Saved in:
  5. 5
    Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model

    Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model 由 Suet Yi Leung, Hideaki Miyake, Tobias Zellweger, Anthony W. Tolcher, Martin Gleave

    出版 2001
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  6. 6
    Association of African-American Ethnic Background With Survival in Men With Metastatic Prostate Cancer

    Association of African-American Ethnic Background With Survival in Men With Metastatic Prostate Cancer 由 Ian M. Thompson, Catherine M. Tangen, Anthony W. Tolcher, E. David Crawford, Mario A. Eisenberger, C. M. Moinpour

    出版 2001
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  7. 7
    A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer

    A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer 由 Anthony W. Tolcher, Leonard J. Appleman, Geoffrey I. Shapiro, Alain C. Mita, Frank Cihon, Arthur Mazzu, P. R. Sundaresan

    出版 2010
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  8. 8
    Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors

    Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors 由 Robert H. Vonderheide, Jennifer M. Burg, Rosemarie Mick, Jennifer A. Trosko, Dongguang Li, M. Naveed Shaik, Anthony W. Tolcher, Omid Hamid

    出版 2013
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  9. 9
    A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors

    A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors 由 David C. Smith, Rashmi Chugh, Amita Patnaik, Kyriakos P. Papadopoulos, Min Wang, Ann M. Kapoun, Lu Xu, Jakob Dupont, Robert Stagg, Anthony W. Tolcher

    出版 2018
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  10. 10
    Efficacy and Safety of the MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series

    Efficacy and Safety of the MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series 由 Noboru Yamamoto, Anthony W. Tolcher, Navid Hafez, Iwona Ługowska, Rodryg Ramlau, Teresa Macarulla, Junxian Geng, Jian Li, Michael Teufel, Angela Märten, Patricia LoRusso

    出版 2024
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  11. 11
    Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA

    Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA 由 Jonathan E. Zuckerman, Ismael Gritli, Anthony W. Tolcher, Jeremy D. Heidel, Dean Lim, Robert J. Morgan, Bartosz Chmielowski, Antoni Ribas, Mark E. Davis, Yun Yen

    出版 2014
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  12. 12
    Phase I Study of GS-3583, an FMS-like Tyrosine Kinase 3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors

    Phase I Study of GS-3583, an FMS-like Tyrosine Kinase 3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors 由 Anthony W. Tolcher, Joshua Brody, Nishanthan Rajakumaraswamy, Michelle Kuhne, Torsten Trowe, Anees M. Dauki, Shantheri Pai, Ling Han, Kai-Wen Lin, Michael Petrarca, Shivaani Kummar

    出版 2024
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  13. 13
    Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer

    Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer 由 Amita Patnaik, Kyriakos P. Papadopoulos, Anthony W. Tolcher, Muralidhar Beeram, Saı̈k Urien, Larry J. Schaaf, Sanaa Tahiri, Tanios Bekaii‐Saab, François Lokiec, Keyvan Rezaï, Aby Buchbinder

    出版 2013
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  14. 14
    Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

    Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles 由 Mark E. Davis, Jonathan E. Zuckerman, Chung Hang Jonathan Choi, David B. Seligson, Anthony W. Tolcher, Christopher A. Alabi, Yun Yen, Jeremy D. Heidel, Antoni Ribas

    出版 2010
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  15. 15
    Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α5β1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study

    Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α5β1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study 由 Alejandro D. Ricart, Anthony W. Tolcher, Glenn Liu, Kyle D. Holen, Garry Schwartz, Mark R. Albertini, Geoffrey R. Weiss, Salim Yazji, Chee M. Ng, George Wilding

    出版 2008
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  16. 16
    First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors

    First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors 由 Kyriakos P. Papadopoulos, Larry Gluck, Lainie P. Martin, Anthony J. Olszanski, Anthony W. Tolcher, Gataree Ngarmchamnanrith, Erik Rasmussen, Benny Amore, Dirk Nagorsen, John S. Hill, Joe Stephenson

    出版 2017
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  17. 17
    First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors

    First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors 由 Timothy A. Yap, Anthony W. Tolcher, Ruth Plummer, Jatinder Kaur Mukker, Marta Enderlin, Christine Hicking, Thomas Grombacher, Giuseppe Locatelli, Zoltán Szűcs, Ioannis Gounaris, Johann S. de Bono

    出版 2024
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  18. 18
    Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma

    Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma 由 Amita Patnaik, Glen J. Weiss, K. Papadopoulos, Craig C. Hofmeister, Raoul Tibes, Anthony W. Tolcher, Robin Isaacs, J. Jac, May Han, Francis Payumo, Monette Cotreau, Rajesh Ramanathan

    出版 2014
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  19. 19
    A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma

    A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma 由 Monica Mita, Patricia LoRusso, Kyriakos P. Papadopoulos, Michael S. Gordon, Alain C. Mita, Roberta Ferraldeschi, Harold Keer, Aram Oganesian, Xiang Yao Su, Simone Jueliger, Anthony W. Tolcher

    出版 2020
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  20. 20
    Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors

    Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors 由 Cristiana Sessa, Patricia LoRusso, Anthony W. Tolcher, Françoise Farace, Nathalie Lassau, Angelo Delmonte, Antonio Braghetti, Rastislav Bahleda, Patrick Cohen, Marie Hospitel, Christine Veyrat‐Follet, Jean‐Charles Soria

    出版 2013
    获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: